AstraZeneca in 2012 - Recensione dipendente - SFE Lead presso AstraZeneca

3,0
19 dic 2013
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Big multinational with strong corporate culture. Good focus on training employees. Average to high salary level, depending on the county. Advanced bonus system.

Svantaggi

Since change of CEO in 2012 the company had massive job cuts and restructuring. Second main office in Brussels was closed with 60% employees leaving. Many local markets changed the top management. After expiration of crestor patent, and failure to introduce new molecules, company is in tough financial situation.

Esplora altre recensioni su AstraZeneca

5,0
24 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

great company that cares about patients and employees growth

Svantaggi

metrics can be difficult for promotion

1,0
19 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The page is friendly to make an application.

Svantaggi

As an experienced healthcare analytics and commercial leader, I applied to 104 U.S.-based positions at AstraZeneca between 2025 and 2026 that closely matched my background. Despite receiving interviews from peer organizations, I did not receive a single recruiter interaction. I fully understand the competitiveness of hiring, but such a complete lack of engagement raises questions about potential overreliance on AI screening or unintended bias.

Vedi recensioni per: Utile|Valutazione|Data|Tutto